{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    13,
    14,
    15,
    16,
    22,
    23,
    24,
    25,
    26,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "BIVV009 Treatment Arm",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "All participants receive BIVV009 IV infusion. Dosing is based on body weight: 6.5g for <75kg or 7.5g for ≥75kg. Dosing schedule: Day 0, Day 7, and then every 14 days thereafter."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Primary CAgD with recent transfusion",
        "instanceType": "StudyCohort",
        "characteristic": "Patients with primary cold agglutinin disease who have a history of at least one documented blood transfusion within 6 months of enrollment."
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "BIVV009 Treatment Arm - Screening/Observation Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for BIVV009 Treatment Arm during Screening/Observation Period"
      },
      {
        "id": "elem_2",
        "name": "BIVV009 Treatment Arm - Part A Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for BIVV009 Treatment Arm during Part A Treatment Phase"
      },
      {
        "id": "elem_3",
        "name": "BIVV009 Treatment Arm - Part B Extension Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for BIVV009 Treatment Arm during Part B Extension Phase"
      },
      {
        "id": "elem_4",
        "name": "BIVV009 Treatment Arm - Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for BIVV009 Treatment Arm during Safety Follow-up"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 4,
      "cohortCount": 1,
      "elementCount": 4
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "controlType": {
        "code": "No Treatment",
        "codeSystem": "USDM",
        "decode": "No Treatment"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1"
      ],
      "therapeuticAreas": [
        "Hematology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": "No Treatment",
      "therapeuticAreas": [
        "Hematology"
      ]
    },
    "arms": [
      {
        "name": "BIVV009 Treatment Arm",
        "type": "Experimental Arm",
        "description": "All participants receive BIVV009 IV infusion. Dosing is based on body weight: 6.5g for <75kg or 7.5g for ≥75kg. Dosing schedule: Day 0, Day 7, and then every 14 days thereafter.",
        "isTitration": false
      }
    ],
    "cohorts": [
      {
        "name": "Primary CAgD with recent transfusion",
        "characteristic": "Patients with primary cold agglutinin disease who have a history of at least one documented blood transfusion within 6 months of enrollment."
      }
    ],
    "epochs": [
      {
        "name": "Screening/Observation Period",
        "description": "Day -42 to Day -1; includes medical history and characterization of CAgD biomarkers."
      },
      {
        "name": "Part A Treatment Phase",
        "description": "Initial 6-month (26 weeks) treatment period to assess efficacy and safety."
      },
      {
        "name": "Part B Extension Phase",
        "description": "Long-term safety and durability of response phase running for 2 years following last patient out from Part A."
      },
      {
        "name": "Safety Follow-up",
        "description": "9 weeks after administration of the last dose of study drug for PK, PD, and ADA collection."
      }
    ]
  }
}